-
公开(公告)号:US08197809B2
公开(公告)日:2012-06-12
申请号:US12523516
申请日:2008-11-24
申请人: Young Woo Park , So-Young Choi , Ji Hyun Park , Jung Yu , Eun-Jung Song , Sungsub Kim , Myeoung Hee Jang , Mi-Ju Park , Je-Ho Lee , Jae Ryoung Hwang
发明人: Young Woo Park , So-Young Choi , Ji Hyun Park , Jung Yu , Eun-Jung Song , Sungsub Kim , Myeoung Hee Jang , Mi-Ju Park , Je-Ho Lee , Jae Ryoung Hwang
IPC分类号: C07K16/00 , G01N33/53 , A61K39/395
CPC分类号: C07K16/2896 , C07K2317/21 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/76
摘要: The present invention relates to a CD9-specific human antibody, more precisely a CD9-specific human antibody composed of human derived CD9-specific complementarity determining region (CDR) and framework region (FR). The human antibody of the present invention recognizes CD9 extracellular loop 2 domain (CD9-ECL2) as an epitope and thereby strongly binding thereto. The human antibody of the present invention also has CD9 antigen neutralizing effect and at the same time inhibiting effect on tumor cell lines. Therefore, it can be effectively used for the prevention and treatment of cancer overexpressing CD9.
摘要翻译: 本发明涉及CD9特异性人抗体,更确切地说,涉及由人衍生的CD9特异性互补决定区(CDR)和框架区(FR)组成的CD9特异性人抗体。 本发明的人抗体识别CD9细胞外环2结构域(CD9-ECL2)作为表位,从而与其强结合。 本发明的人抗体也具有CD9抗原中和作用,同时对肿瘤细胞株具有抑制作用。 因此,它可以有效地用于预防和治疗过度表达CD9的癌细胞。
-
公开(公告)号:US20110195027A1
公开(公告)日:2011-08-11
申请号:US12523516
申请日:2008-11-24
申请人: Young Woo Park , So-Young Choi , Ji Hyun Park , Jung yu , Eun-Jung Song , Sungsub Kim , Myeoung Hee Jang , Mi-Ju Park , Je-Ho Lee , Jae Ryoung Hwang
发明人: Young Woo Park , So-Young Choi , Ji Hyun Park , Jung yu , Eun-Jung Song , Sungsub Kim , Myeoung Hee Jang , Mi-Ju Park , Je-Ho Lee , Jae Ryoung Hwang
IPC分类号: A61K49/06 , C07K16/28 , C07H21/04 , A61K39/395 , A61K49/00 , A61P35/00 , C12N15/63 , C12N5/10 , C12P21/06 , G01N33/574
CPC分类号: C07K16/2896 , C07K2317/21 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/76
摘要: The present invention relates to a CD9-specific human antibody, more precisely a CD9-specific human antibody composed of human derived CD9-specific complementarity determining region (CDR) and framework region (FR). The human antibody of the present invention recognizes CD9 extracellular loop 2 domain (CD9-ECL2) as an epitope and thereby strongly binding thereto. The human antibody of the present invention also has CD9 antigen neutralizing effect and at the same time inhibiting effect on tumor cell lines. Therefore, it can be effectively used for the prevention and treatment of cancer overexpressing CD9.
摘要翻译: 本发明涉及CD9特异性人抗体,更确切地说,涉及由人衍生的CD9特异性互补决定区(CDR)和框架区(FR)组成的CD9特异性人抗体。 本发明的人抗体识别CD9细胞外环2结构域(CD9-ECL2)作为表位,从而与其强结合。 本发明的人抗体也具有CD9抗原中和作用,同时对肿瘤细胞株具有抑制作用。 因此,它可以有效地用于预防和治疗过度表达CD9的癌细胞。
-